As a hospitalist on the Medical Transplant team who sees kidney and/or pancreas transplant patients, I come across many cases of chronic allograft nephropathy, which has been identified as the most common cause of re-transplantation and the fourth-leading cause of dialysis after successful transplantation. Small case studies have demonstrated that such patients with allograft nephropathy may benefit from the discontinuation of calcineurin inhibitors, like tacrolimus and cyclosporine, and substitution with sirolimus.
From 2000 until now, about 350 patients with allograft nephropathy have been routinely switched from calcineurin inhibitors to sirolimus-based therapy. My research work centers on analyzing the data of these patients to determine any patient or allograft-related factors that lead to improvement or no improvement in kidney function following the conversion therapy.
Faculty members: Update your contact information and create a profile.